Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer

Abstract

Objective

To compare estimated survival times of patients who had received maintenance monotherapy with gemcitabine (GEM), or an immuno-oncology (IO) drug (i.e., pembrolizumab or avelumab) or both therapies (one after the other) following platinum-based combination chemotherapy for metastatic urothelial carcinoma (UC) in a real-world setting.

Methods

For this retrospective study, we included consecutive patients with metastatic UC who had received first-line platinum-based chemotherapy followed by second-line treatment at our centre from March 2008 to June 2020.

Results

Of the 74 patients identified, 58 had received monotherapy as second line treatment, and 16 had received combination chemotherapy (i.e., non-monotherapy). The estimated median duration of survival was significantly longer in the monotherapy group compared with the non-monotherapy group (29 vs 7 months). Multivariate analysis showed that the outcome of the first-line chemotherapy treatment was the most important prognostic factor for survival. There was no significant difference in survival times between monotherapy with GEM or IO drugs. In addition, survival was significantly prolonged when GEM therapy was administered following IO drugs compared with GEM therapy alone.

Conclusion

Monotherapy following primary chemotherapy for advanced UC significantly prolonged survival times, and IO drug therapy remained effective when followed by GEM single agent maintenance therapy.

Keywords

Urothelial cancer monotherapy immune-oncology second-line treatment gemcitabine

Introduction

Urothelial carcinoma (UC) is a malignant tumour of the upper (i.e., renal pelvis, and ureters) and lower (i.e., bladder, and urethra) urinary tract and is the sixth most common tumour in developed countries.¹ The most common type of UC is bladder cancer.² Metastatic UC is known to progress rapidly and has a poor prognosis with estimated median overall survival of approximately a year.^3,4 The mainstay of treatment for metastatic UC is platinum-based combination chemotherapy, and gemcitabine (GEM) plus cisplatin is the most widely used first-line therapy.⁵ Generally, UC is highly sensitive to chemotherapy and the initial response rate has been reported to be around 50–70%.⁵ In patients with impaired renal function, carboplatin has been used instead of cisplatin and response rate of approximately 40% have been observed with survival rates equivalent to that of cisplatin.^6,7 Because cisplatin causes cumulative nephrotoxicity and neurotoxicity, the use of GEM plus cisplatin as primary chemotherapy has been limited to six cycles.^5,8 Interestingly, one study showed that five or more cycles of the initial platinum-based chemotherapy did not prolong overall survival compared with four cycles, and suggested that four cycles of chemotherapy may be sufficient.⁹

Following platinum-based chemotherapy, there is no internationally accepted standard of care for second-line therapy.¹⁰ The development of immuno-oncology (IO) agents, such as pembrolizumab and avelumab have added to the options available in the second-line setting.^10,11 However, before the introduction of IO drugs, monotherapy with cytotoxic agents was used as follow-up treatment until disease progression.^12,13 In our department, we have often used GEM as maintenance monotherapy after primary chemotherapy in advanced UC.

The aim of our retrospective study from a real-world setting was to compare estimated survival times of patients who had received maintenance monotherapy with GEM, or an IO drug (i.e., pembrolizumab or avelumab) or both therapies (one after the other) following platinum-based combination chemotherapy for metastatic UC. In addition, we investigated potential prognostic factors for survival.

Methods

We retrospectively reviewed data from consecutive patients with metastatic UC who had received platinum-based chemotherapy at our centre from March 2008 to June 2020. We separated patients into those who had received further combination therapy, or monotherapy with GEM and/or IO drug (pembrolizumab or avelumab) following their first line treatment.

GEM dosing was based on the standard infusion dose (1000 mg/m²) and dosing intervals (Day 1 and Day 8/every 3 weeks), pembrolizumab was given at 200 mg IV every three weeks, and avelumab at 10 mg/kg IV every two weeks. At the discretion of the attending physician, the dosing interval and doses were adjusted according to the patient's condition. None of the patients had a history of systemic anticancer therapy for advanced or metastatic disease. Treatment results for metastatic sites following first-line chemotherapy were evaluated based on the Response Evaluation Criteria in Solid Tumours (RECIST) guidelines (i.e., complete response [CR], partial response [PR], stable disease [SD], or progressive disease [PD]).¹⁴ Termination of each therapy was at the discretion of the attending physician following observation of any side effects or clinical progression.

The reporting of this study conforms to STROBE guidelines,¹⁵ and was approved by the Institutional Review Board and the Research Ethics Committee of Nihon University School of Medicine (RK-190611-3). Informed consent was obtained based on an opt-out method and patient details were de-identified.

Statistical analyses

Statistical analyses were performed using SPSS Statistics (IBM Japan, Tokyo, Japan) and JMP® version 14 (SAS Institute Japan, Inc., Tokyo, Japan). A P-value <0.05 was considered to indicate statistical significance. Continuous data were presented as mean ± standard deviation and Student's t-test was used to compare results between groups. Categorical variables were compared using χ² test and Fisher’s exact tests. Univariate and multivariate logistic regression analyses were performed to identify appropriate prognostic factors based on patient characteristics for advanced UC. Significant factors from univariate analysis were subjected to multivariate analysis. Survival analyses were conducted according to the Kaplan-Meier method and survival characteristics were compared using log-rank tests.

Results

Of the 74 patients with UC who had received first-line platinum-based chemotherapy at our centre during the study period, 21 had received neoadjuvant/adjuvant therapy, 19 were classed as PD and 34 were classed as CR/PR/SD (Figure 1). Of the 74 patients, 58 subsequently received monotherapy as second line treatment, and 16 received further combination chemotherapy (i.e., non-monotherapy; Figure 1). While there was no difference between groups in mean age (69 vs 73 years), more patients in the non-monotherapy group compared with the monotherapy group had advanced disease (TNM classification, P = 0.008; regional lymph nodes, P = 0.005, distant metastases, P = 0.018; Table 1). By contrast, following primary therapy, there were no statistically significant differences between groups in the number of primary tumour resections (44% and 59% for non-monotherapy and monotherapy groups, respectively), or in the number of cases that had received neoadjuvant/adjuvant therapy (25% and 29% for non-monotherapy and monotherapy groups, respectively). In addition, there was no difference in the number of patients with metastases (75% and 71%, for non-monotherapy and monotherapy groups, respectively) or in outcomes of metastatic sites based on RECIST guidelines (Table 1).

Figure. 1.

Patient flowchart.

Table 1.

Patient characteristics and outcomes for those who received first-line chemotherapy (n = 74).

Variable	Followed by monotherapy(n = 58)	Followed by non-monotherapy(n = 16)	Statistical significance
At start of first-line chemotherapy
Age, y	69 ± 8	73 ± 8	ns
Primary tumour, TNM classification,
T1	6 (10)	0 (0)	P = 0.008
T2	20 (34)	3 (19)
T3	23 (40)	4 (25)
T4	9 (16)	9 (56)
Regional lymph nodes
≥N1	23 (40)	13 (81)	P = 0.005
Distant metastases
M1	10 (17)	8 (50)	P = 0.018
At end of first-line chemotherapy
No. cases with resected primary tumors	34 (59)	7 (44)	ns
Neoadjuvant or adjuvant therapies	17 (29)	4 (25)	ns
No. patients with metastases	41 (71)	12 (75)	ns
Outcome for metastatic sites			ns
Complete response	7 (17)	0 (0)
Partial response	11 (27)	1 (8)
Stable disease	10 (24)	5 (42)
Progressive disease	13 (32)	6 (50)

Data are expressed as, mean ± standard deviation, or n (%).

ns, not statistically significant.

The estimated median duration of survival was significantly longer in the monotherapy group compared with the non-monotherapy group (29 vs 7 months, P = 0.003) (Figure 2a). We compared response to first-line chemotherapy for all patients (n = 74) and unsurprisingly found that patients with PD had the shortest median survival compared to other groups (PD, 5 months; CR/PR/SD, 29 months; patients with neoadjuvant/adjuvant therapies, 36 months; P < 0.001, Figure 2b).

Figure. 2.

(a). Survival in patients who received either monotherapy or non-monotherapy (i.e., combination therapy) following first-line chemotherapy (n = 74). The difference between the two curves was statistically significant (P = 0.003).

We analysed prognostic factors for survival based on patient characteristics for advanced UC. These were: age (<70 vs ≥70 years); resected primary tumour; TNM classification (≤2 vs >2); regional lymph nodes (≥N1); distant metastases (0 vs 1); outcome following first-line therapy (Others vs PD); monotherapy vs non-monotherapy. Multivariate analysis showed that the outcome of first-line chemotherapy was the most significant prognostic factor for survival (hazard ratio 15.5, 95% CI, 4.9–49, P < 0.001; Table 2).

Table 2.

Univariate and multivariate proportional hazard analyses of prognostic factors for survival (n = 74).

Variable	Univariate			Multivariate
Variable	Hazard ratio	95% CI	Statistical significance	Hazard ratio	95% CI	Statistical significance
Age, y (<70 vs. ≥70)	1.66	0.86–3.20	ns
Resected primary tumor	0.55	0.28–1.08	ns
TNM (≤2 vs. >2)	0.85	0.44–1.63	ns
*N (0 vs. 1 or more)	2.32	1.20–4.50	P = 0.012	1.94	0.93–4.03	ns
^αM (0 vs. 1)	2.93	1.51–5.68	P = 0.001	1.89	0.86–4.12	ns
Outcome following first-line chemotherapy (Others vs. PD)	16.6	5.8–48	P < 0.001	15.5	4.9–49	P < 0.001
Non-monotherapy vs. monotherapy	0.37	0.18–0.74	P = 0.005	0.54	0.24–1.21	ns

*Regional lymph nodes

Distant metastases

CI, confidence interval; ns, not statistically significant; CR, complete response, PR, partial response; SD, stable disease; PD: progressive disease.

We compared differences in patient characteristics and outcomes among patients that had received GEM (n = 26), IO drugs (n = 23) or both treatments (one after the other) (n = 9) (Table 3). Although most patients with PD were in the IO drug group (86% vs 5% vs 0%; P < 0.001, Table 3), there was no significant difference in survival times between GEM and IO-treated cases (GEM, 29 months; IO, 28 months; P = 0.405, Figure 3a). However, patients who received IO monotherapy followed by GEM monotherapy (n = 9) showed a significantly better prognosis than those who received only GEM monotherapy (n = 26). Estimated survival times were 29 months, and ‘not reached’, for GEM group and IO followed by GEM group, respectively (P = 0.047, Figure 3b).

Table 3.

Comparison between monotherapy treatment groups (n = 58)

	GEM(n = 26)	IO drugs*(n = 23)	Both (GEM followed by IO) (n = 9)	Statistical significance
At start of first-line chemotherapy
Age, y	70 ± 6	69 ± 10	67 ± 11	ns
Primary tumour, TNM classification
T1	1 (4)	3 (13)	2 (22)	ns
T2	6 (23)	10 (43)	4 (44)
T3	14 (54)	7 (30)	2 (22)
T4	5 (19)	3 (13)	1 (11)
Regional lymph nodes
N1 or more	23 (88)	13 (57)	8 (89)	P = 0.025
Distant metastases
M1	7 (27)	2 (9)	1 (11)	ns
At end of first-line chemotherapy
No. cases with resected primary tumors	11 (42)	17 (74)	6 (67)	ns
No. courses of chemotherapy prior to monotherapy				ns
1	23 (88)	20 (87)	8 (89)
2	3 (12)	3 (13)	1 (11)
Neo-adjuvant or adjuvant therapies	7 (27)	9 (39)	1 (11)
No. patients with metastases	19 (73)	14 (61)	8 (89)
Outcome for metastatic sites				P < 0.001
Complete response	3 (16)	1 (7)	3 (38)
Partial response	7 (37)	1 (7)	3 (38)
Stable disease	8 (42)	0 (0)	2 (25)
Progressive disease	1 (5)	12 (86)	0 (0)

Data are expressed as, mean ± standard deviation, or n (%).

*Pembrolizumab or avelumab.

GEM, gemcitabine; IO, immune-oncology; ns, not statistically significant.

Figure. 3

(a) Kaplan-Meier estimates of survival times between gemcitabine (GEM) monotherapy and immuno-oncology (IO) drug treatment groups. There was no significant difference between these two groups (GEM, 29 months; IO, 28 months; P = 0.405) and (b) Kaplan-Meier estimates of survival times stratified using IO drugs followed by GEM monotherapy. IO drug treatment followed by GEM monotherapy showed a significant prolonged survival time compared with GEM monotherapy alone (GEM, 29 months; IO followed by GEM, not reached; P = 0.047).

Discussion

Advanced and metastatic UC account for the majority of deaths associated with this disease.¹⁶ In a large retrospective study on metastatic upper UC, the most common site of metastasis was identified as the distant lymph nodes, and liver metastasis was found to be a poor prognostic factor, whereas primary tumour resection and chemotherapy were predictors of better survival outcome.¹⁷ The development of cisplatin-based combination chemotherapy has extended median survival from several to 11–15 months.¹⁶ However, the prognosis for metastatic patients with no response to primary chemotherapy is poor.¹⁸ In addition, long term treatment with platinum may result in severe adverse effects. The combination of GEM and cisplatin combination has been reported to be less toxic than the combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) but with similar efficacy.¹⁹ Moreover, we have often used GEM as maintenance monotherapy after primary chemotherapy in advanced UC. The emergence of immune checkpoint inhibitors, such as pembrolizumab and avelumab, has also provided alternative treatments for second-line therapy in metastatic UC.^10,11

We conducted a retrospective, real world review of patients who had received monotherapy following platinum-based combination chemotherapy for metastatic UC at our centre over a 12-year period. We investigated estimated survival times and possible prognostic factors for survival. Maintenance monotherapy was GEM, or an IO drug (i.e., pembrolizumab or avelumab) or both (i.e., one treatment after the other). We found that patients who received monotherapy had a significant increase in survival times compared with those that had received further combination therapy. While at the time of diagnosis, the combination (i.e., non-monotherapy) group had a higher rate of advanced disease than the monotherapy group, there was no difference between groups in overall response to primary chemotherapy. However, RECIST-defined progressive disease (PD) following first-line treatment was found to be an important prognostic factor for survival.

Despite more PD cases in the IO drug group, there was no difference in survival times between the IO drug group and the GEM group. These data suggest that advanced UC is highly sensitive to IO agents. However, one study found that the average duration of prolonged prognosis following pembrolizumab used as second-line therapy for UC was as short as three months.¹⁰ Monotherapy with cytotoxic agents, such as GEM, has shown favourable results in previous studies.^12,13 While median survival for GEM maintenance chemotherapy was reported to be approximately 12–15 months,^12,13 we found the median survival time was significantly longer at 29 months in GEM group and 28 months in IO drug group. The difference between our study and previous results may be due to the longer observation period of our study compared with others.

We found that patients treated with IO drugs followed by GEM had a longer survival time compared with GEM monotherapy, suggesting a favourable relationship between GEM and the IO drugs. In previous studies, it has been reported that a decrease in cytidine, which is the main effect of GEM, activates interferon (IFN)-responsive genes.²⁰ Furthermore, IFN-α has been shown to be involved in conflicting immune responses (e.g., activating T lymphocytes while promoting the PDL1 expression) suggesting a possible explanation for the efficacy of IFN-α and PD-1/PD-L1 antibody combination therapy against the PD-1/PD-L1 antibody-resistant cancer.²¹ Our findings suggest that GEM monotherapy as a second-line therapy may affect subsequent PD-1/PD-L1 antibody sensitivity.

Our study had several limitations including its retrospective design and its low number of patients. In addition, we included patients who received adjuvant/neoadjuvant chemotherapy as part of first-line treatment. As shown by our findings, these patients tend to have a longer survival rate than patients who do not receive adjuvant/neoadjuvant therapy. Nevertheless, this is the first study to demonstrate the benefit of GEM monotherapy for advanced UC in the advent of IO drugs. Moreover, our findings suggest that second-line IO drug monotherapy remains effective if followed by GEM monotherapy.

Supplemental Material

sj-pdf-1-imr-10.1177_03000605231173319 - Supplemental material for Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer

Supplemental material, sj-pdf-1-imr-10.1177_03000605231173319 for Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer by Hideaki Uchida, Daisuke Obinata, Shogo Takada, Tsuyoshi Yoshizawa, Junichi Mochida, Kenya Yamaguchi and Satoru Takahashi in Journal of International Medical Research

Supplemental Material

sj-pdf-2-imr-10.1177_03000605231173319 - Supplemental material for Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer

Supplemental material, sj-pdf-2-imr-10.1177_03000605231173319 for Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer by Hideaki Uchida, Daisuke Obinata, Shogo Takada, Tsuyoshi Yoshizawa, Junichi Mochida, Kenya Yamaguchi and Satoru Takahashi in Journal of International Medical Research

Footnotes

Acknowledgements

The authors thank Ms. Naoko Kodaka for her secretarial assistance. We acknowledge technical assistance from Mr. Mitsuo Kano and Ms. Yuki Ikemori. We would like to thank Editage () for English language editing.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This work was funded by JSPS KAKENHI (grant numbers JP19H03793 and JP19K09740).

ORCID iDs

Daisuke Obinata

Kenya Yamaguchi

References

Siegel

Miller

Jemal

Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.

Reuter

VE.

The pathology of bladder cancer. Urology 2006; 67: 11–17; discussion 17–18.

Lenis

Lec

Chamie

, et al. Bladder Cancer: A Review. JAMA 2020; 324: 1980–1991.

Galsky

Moshier

Krege

, et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer 2013; 119: 3012–3019.

Abe

Minami

Harabayashi

, et al. Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma. Jpn J Clin Oncol 2019; 49: 965–971.

De Santis

Bellmunt

Mead

, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30: 191–199.

Dogliotti

Carteni

Siena

, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007; 52: 134–141.

Chovanec

Abu Zaid

Hanna

, et al. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol 2017; 28: 2670–2679.

Yamamoto

Kato

Takeyama

, et al. A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinoma. Urol Oncol 2022; 40: 194 e7–194.

10.

Bellmunt

De Wit

Vaughn

, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017; 376: 1015–1026.

11.

Powles

Park

Voog

, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2020; 383: 1218–1230.

12.

Kim

Lee

Kim

, et al. Gemcitabine maintenance versus observation after first-line chemotherapy in patients with metastatic urothelial carcinoma: a retrospective study. Transl Androl Urol 2020; 9: 2113–2121.

13.

Muto

Abe

Noguchi

, et al. Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer. Int J Urol 2015; 22: 490–494.

14.

Eisenhauer

Therasse

Bogaerts

, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.

15.

Von Elm

Altman

Egger

, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147: 573–577.

16.

Katims

Reisz

Nogueira

, et al. Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma. Cancers (Basel) 2022; 14: 5431.

17.

Tufano

Cordua

Nardone

, et al. Prognostic Significance of Organ-Specific Metastases in Patients with Metastatic Upper Tract Urothelial Carcinoma. J Clin Med 2022; 11: 5310.

18.

Yafi

North

Kassouf

First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol 2011; 18: e25–e34.

19.

Bilim

Kuroki

Shirono

, et al. Advanced Bladder Cancer: Changing the Treatment Landscape. J Pers Med 2022; 12: 1745.

20.

Lee

Kim

Jang

, et al. Gemcitabine, a broad-spectrum antiviral drug, suppresses enterovirus infections through innate immunity induced by the inhibition of pyrimidine biosynthesis and nucleotide depletion. Oncotarget 2017; 8: 115315–115325.

21.

Liang

Tang

Guo

, et al. Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nat Commun 2018; 9: 4586.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.10 MB

0.20 MB